These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29049036)

  • 1. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
    Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
    Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
    Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
    FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
    Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
    Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
    Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
    Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
    Minami J; Suzuki R; Mazitschek R; Gorgun G; Ghosh B; Cirstea D; Hu Y; Mimura N; Ohguchi H; Cottini F; Jakubikova J; Munshi NC; Haggarty SJ; Richardson PG; Hideshima T; Anderson KC
    Leukemia; 2014 Mar; 28(3):680-9. PubMed ID: 23913134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway.
    Li X; Guo Y; Kuang X; Zhao L; Li H; Cheng B; Wang W; Zhang Z; Liu P; Wang J
    Life Sci; 2019 Apr; 223():146-157. PubMed ID: 30876940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.
    Kuang X; Xiong J; Wang W; Li X; Lu T; Fang Q; Wang J
    Life Sci; 2019 Feb; 219():248-256. PubMed ID: 30658101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway.
    Zhang Z; Mao H; Du X; Zhu J; Xu Y; Wang S; Xu X; Ji P; Yu Y; Cao B; Han K; Hou T; Xu Z; Kong Y; Jiang G; Tang X; Qiao C; Mao X
    Oncotarget; 2016 Feb; 7(8):9296-308. PubMed ID: 26814430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
    Zhang T; Jiang B; Zou ST; Liu F; Hua D
    World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
    Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
    Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
    Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
    Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
    Li F; Rajendran P; Sethi G
    Br J Pharmacol; 2010 Oct; 161(3):541-54. PubMed ID: 20880395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
    Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.